Navigation Links
NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:4/1/2009

3,039 2,500 Total current liabilities 4,578 4,480 Capital lease obligation - non-current 49 7 Equipment loan - non-current 497 470 Deferred revenue - non-current 4,478 1,667 Total liabilities 9,602 6,624 Stockholders' Equity: Common stock, $0.01 par value; 65,000 and 65,000 shares authorized at December 31, 2007 and December 31, 2008, respectively, 21,269 and 21,471 shares issued and outstanding at December 31, 2007 and December 31, 2008, respectively. 212 215 Additional paid-in capital 32,585 33,718 Accumulated other comprehensive income (loss) (3) - Accumulated deficit during development stage (18,474) (26,588) Total stockholders' equity 14,320 7,345 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $23,922 $13,969 CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) Cumulative Period from July 1, 2002 (date of development stage inception) to Year Ended December 31, December 31, 2006 2007 2008 2008 REVENUE License and collaboration revenue $1,533 $5,913 $6,722 $14,168 Total revenue
'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
3. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
10. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... including DESY scientists has observed tiny quantum vortices in ... the journal Science that the exotic vortices ... It is the first time that the quantum vortices, ... what is known as superfluid helium, have been detected ... says Andrey Vilesov of the University of Southern California, ...
(Date:8/21/2014)... August 21, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... therapy, is a means of replacing hormones ... the body. This type of therapy is ...
(Date:8/21/2014)... 21, 2014 Telomere Biosciences, LLC (Telomere ... "TELO-20 for Dogs" with Telomerase Activation Complex ... the world for dogs. Telomeres are the protective ... the body. A wealth of ground-breaking research by ... Science and Aging, including Nobel laureates, has demonstrated ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... Brazil and ... The uptake of several newly approved agents, the ... this indication and the launch of emerging biologics ... markets. In particular, the emerging IL-5 inhibitors will ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... ... extend the life of the International Space Station (ISS) to 2020 or beyond. , ... (Vocus) February 1, 2010 -- Astrogenetix ... Space Station (ISS) to 2020 or beyond. , ,Thomas B. Pickens III, Chairman of Astrogenetix, ...
... Feb. 1 Zimmer Holdings, Inc. (NYSE: ... OMeGA Medical Grants Association LLC (OMeGA) $2.175 million in ... as a third party administrator for graduate medical education.  Zimmer was ... funding for educational grants for the 2009-2010 academic year; the Company ...
... , , TSX Exchange Symbol: RVX ... ("Resverlogix" or the "Company") (TSX:RVX) announced today that the Board ... of Bayer HealthCare and Chairman of the Bayer HealthCare Executive ... , Mr. Higgins joined Bayer in 2004 as Chairman of ...
Cached Biology Technology:Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement 2Zimmer Holdings Announces 2010 Funding for OMeGA Medical Grants Association 2Zimmer Holdings Announces 2010 Funding for OMeGA Medical Grants Association 3Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors 2Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors 3Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors 4
(Date:8/22/2014)... birds and the bees. But that old expression ... The fertilization process for flowering plants is particularly ... and female reproductive cells. New research from an ... and including Carnegie,s Wolf Frommer, David Ehrhardt, and ... process that guides flowering plant fertilization. It is ...
(Date:8/21/2014)... 21, 2014 Nxt-ID, Inc. (OTCQB: NXTD), a ... market, announced today that its shares of common stock ... issued in its proposed underwritten public offering of common ... The Nasdaq Capital Market, subject to closing of its ... warrants, and will trade under the symbol "NXTD" and ...
(Date:8/21/2014)... 21, 2014 /PRNewswire-iReach/ -- LiveScan Service Provider  ... to a partnership with Gabriel Health Institute, one ... growing Certified Nursing Assistant preparatory schools. The ... exclusive member of Binary,s LiveScan service provider,s owner/operator ... improve its service capabilities by widening the ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3
... computed tomography (CT) evaluation of King Tutankhamun’s mummy believe ... pharaoh died. The CT images and results of their ... the Radiological Society of North America (RSNA). , Ashraf ... University in Egypt, was part of an international team ...
... elongated neck has long been used in textbooks as ... common example has received very little experimental attention. In ... the Mammal Research Institute in the Department of Zoology ... foraging competition with shorter herbivores could explain why giraffes ...
... new ultrasound technique allows radiologists to accurately distinguish ... researchers correctly identified both cancerous and harmless lesions ... findings were presented today at the annual meeting ... , “In our work, elasticity imaging has been ...
Cached Biology News:Radiologists attempt to solve mystery of Tut's demise 2Elasticity imaging identifies cancers and reduces breast biopsies 2
... Mung Bean Nuclease catalyzes the degradation ... yield 5-phosphoryl terminated products. While the nuclease ... very high concentrations the enzyme degrades double-stranded ... Nuclease has been used for transcript mapping ...
... The S.c. EasyComp Transformation Kit is ... Saccharomyces cerevisiae cells. Advantages over commonly ... formation or LiCl methods include:- Cells can ... 30 minutes - Competent cell preparation and ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
...
Biology Products: